Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04887831 · ClinicalTrials.gov registry record · Phase 2
Trilaciclib, a CDK 4/6 Inhibitor, in Patients With Advanced/Metastatic Bladder Cancer Receiving Chemotherapy Then Avelumab
A Phase 2 study, sponsored by G1 Therapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 92
- Enrollment target
NCT04887831 is a Phase 2 study that was terminated before completion, run by G1 Therapeutics. The registered enrollment target is 92 participants.
The verdict
NCT04887831, a Phase 2 study, was terminated before completion, sponsored by G1 Therapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 92 participants
- Enrollment target
Study Summary
This is a Phase 2, multicenter, randomized, open-label study evaluating the safety and efficacy of trilaciclib administered with platinum-based chemotherapy followed by trilaciclib administered with avelumab maintenance therapy compared with platinum-based chemotherapy followed by avelumab maintenance therapy in participants receiving first-line treatment for advanced/metastatic urothelial carcinoma.
Interventions
- DRUG Carboplatin
- DRUG Cisplatin
- DRUG Gemcitabine
- DRUG Avelumab
- DRUG Trilaciclib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 92 participants |
| Start Date | 2021-06-04 |
| Est. Completion | 2024-03-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04887831
The ClinicalTrials.gov registry entry for NCT04887831 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 92 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is G1 Therapeutics, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Carboplatin is the first listed.
NCT04887831 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04887831 about?
NCT04887831 is a clinical study titled "Trilaciclib, a CDK 4/6 Inhibitor, in Patients With Advanced/Metastatic Bladder Cancer Receiving Chemotherapy Then Avelumab". This is a Phase 2, multicenter, randomized, open-label study evaluating the safety and efficacy of trilaciclib administered with platinum-based chemotherapy followed by trilaciclib administered with avelumab maintenance therapy compared with platinum-based chemotherapy followed by avelumab maintenan...
What is the current status of trial NCT04887831?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 92 participants. The study started on 2021-06-04. Estimated completion is 2024-03-01.
What interventions are being tested in trial NCT04887831?
The interventions under investigation include: Carboplatin (DRUG), Cisplatin (DRUG), Gemcitabine (DRUG), Avelumab (DRUG), Trilaciclib (DRUG).
Who is sponsoring clinical trial NCT04887831?
This trial is sponsored by G1 Therapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.